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Abstract  
Gabapentin is being studied for use after high-level spinal cord injury (above thoracic level five) 
to prevent abnormal neuron sprouting and aberrant synaptogenesis which causes a life threatening 
condition Autonomic Dysreflexia (AD). Without treatment, AD causes high blood pressure which can 
induce stroke, seizures, and even death. It is theorized that gabapentin will reduce swelling around the 
site of injury which will enhance axon growth and plasticity culminating in improved recovery of 
neurological function after spinal cord injury. High performance liquid chromatography electrospray 
ionization time-of-flight mass spectroscopy (HPLC-ESI-TOF-MS) was used for the quantification of 
gabapentin in tissue serum samples. Solutions of samples were prepared and concentrations of drug 
were determined on the basis of calibration curves created using standards prepared. The samples were 
spiked with an internal standard directly after tissue harvest and prior to any further manipulation to 
correct for variations in sample preparation and analysis. This separation and detection method is 
suitable for quantitative sample analysis at low concentrations. With the developed method, it has been 
shown that HPLC-ESI-TOF-MS is capable of determining the concentrations of gabapentin in serums. This 
method of detection will assist neuroscientists in the determination of efficacious dosages as well as 
administration methods. 
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1. Introduction  
1.1 Gabapentin 
 Gabapentin, 1-(aminomethyl-1-cyclohexyl)acetic acid (GBP) (Figure 1), is an antiepileptic drug 
designed from ϒ- aminobutyric acid (GABA). GBP is able to cross the blood-brain barrier and is employed 
for the treatment of partial and generalized tonic-clonic seizures in adults and children.1,2 It has also 
been shown to ease chronic neuropathic pain.3 More recently, it has been shown as an anti-
epileptic/anti-neuropathic pain drug, gabapentin (NeurontinTM) binds with α2δ-1 thereby blocking 
thrombospondins (TSP)/neuronal α2δ-1 interactions as well as inhibiting TSP-induced new synapse 
formation.4,5 By inhibiting TSP binding to neuronal, it is hypothesized that gabapentin will reduce the 
severity and frequency of Autonomic Dysreflexia (AD) by inhibiting maladaptive synaptogenesis after 
spinal cord injury.  
  
 
 
 
 
 
 
Figure 1: chemical structures of (A) gabapentin in balanced neutral and zwitterionic form and (B) internal standard (caffeine) 
 
GBP is currently under investigation by The Ohio State University Department of Neurology for 
use after high-level spinal cord injury (above thoracic level five (T5)) to prevent abnormal neuron 
sprouting and aberrant synaptogenesis which causes AD. AD is a life threatening condition of episodic 
vascular hypertension (often with bradycardia, or slowed heart rate) that develops in most 
(approximately 90%) of the 300,000 new cases a year of spinal cord injury (SCI) above thoracic spinal 
(A) (B) 
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level T5. 6,7 AD is an abrupt, uncontrolled sympathetic response caused by stimulus below the level of 
injury and can lead to severe hypertension, cerebral hemorrhage, and death.8 After high level SCI, loss of 
supraspinal control together with aberrant collateral sprouting and formation of new intraspinal 
synapses causes spinal autonomic reflexes to become exaggerated. 9,10 This post-injury maladaptive 
neural plasticity, involving sensory axons and propriospinal interneurons that connect multiple segments 
of the thoracic and upper lumbar spinal cord, progresses slowly over the course of several weeks or 
months post-injury. This results in an increased blood pressure response during bladder distention or 
other common stimulus below the level of injury in SCI patients. 11 
Prevention (e.g., regular bladder/bowel voiding) and anti-hypertensive medications are 
currently the best way to “manage” AD; however, there is no cure.12 In this study, concentrations of GBP 
will be quantified in spinal cord samples of mice in order to determine a dosage and delivery method to 
use on a full scale experiment where genetic and pharmacological tools will be used to test the 
hypothesis that post-injury inhibition of reactive synaptogenesis will block the onset or reduce the 
severity of AD. 
GBP’s bioavailability may vary greatly between subjects because of its particular active 
absorption by the gut and excretion by the kidney due to dose- dependent oral absorption kinetics and 
dose- independent disposition kinetics. 13,14 It is also not known in what concentrations GBP will present 
itself in the spinal cord for this treatment purpose given different delivery methods and how it will be 
digested in the body for dosage purposes. It is for these reasons that the quantification of GBP in spinal 
cord samples will be useful to neurology researchers in evaluating GBP dosage and delivery methods 
before moving to a full scale experiment of use in post- spinal injury cases.  
Although gabapentin is currently widely used for seizures and neuropathic pain management, its 
bioavailability is still not well understood. Many analytical techniques have been implemented and 
reported for the quantitative determination of gabapentin in tissue, plasma, or serum including: high- 
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performance liquid chromatography (HPLC) with UV detection15, HPLC coupled with electrospray 
tandem mass spectroscopy (ESI-MS)16, liquid chromatography tandem MS (LC-MS/MS)17, gas-liquid 
chromatography (GLC) with flame ionization (FI)18, and capillary electrophoresis (CE) with laser-induced 
fluorescence (LIF) detection19. However, using conventional HPLC, GC, or CE methods require long work 
up processes to extract GBP from biological samples. 
 HPLC with UV detection method required a reversed-phase solid-phase extraction which 
involves placing plasma samples in a glass culture tube with an internal standard and buffer followed by 
activation of a solid-phase extraction cartridge and finally passing the mixture through a conditioned 
cartridge by gravity followed by buffer and acid washes and then eluting the cartridge with methanol.  
This work up process is then followed by a derivatization which includes base which is added to the 
eluent and dried under nitrogen to which a derivatizing agent, phenylisothiocyanate in this case, was 
added to react with the residue for 20 minutes which was then dried under nitrogen again. The sample 
went on to be reconstituted with mobile phase and then analyzed with a run time of 8 minutes and a 
detection limit of 30 ppb. 15 GLC-FI determination of gabapentin in serum also required a lengthy 
workup procedure before the samples were able to be run. The method required an extraction of 
acidified sample by solid- phase column, derivatization (agent added then solution put into a water bath 
(70 °C) for 30 minutes, then cooled 10 minutes), and then analysis on an HP-1 column (5 minutes) with 
FI detector. This resulted in a limit of detection of 200 ppb with a limit of quantification of 500 ppb, 
linear range from 500 ppb to 30 ppm. 18 The CE-LIF analysis method also required a derivatization 
procedure using 6-carboxyfluorescein succinimidyl ester vortexed with the sample for 30 minutes 
resulting in a limit of detection of 10.3 ppb (60nM). 19 
This is in direct contrast to the sample preparation required to run an HPLC-ESI-MS. This analysis 
method requires the sample to be vortexed (20 seconds) with the internal standard before acetonitrile 
is added and vortexed again (20 seconds) then centrifuged (10 minutes) when the upper layer is then 
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removed and diluted with mobile phase before being run with a run time of 4 minutes with a lower limit 
of quantification of 50 ppb in the linear range (50 ppb- 10 ppm).16 This extraction process closely mimics 
the HPLC- MS/MS method used which also included a simple protein precipitation workup before 
samples were run with a limit of detection of 10 ppb and a lower limit of quantification of 40 ppb with a 
run time of only 2 minutes.17   
The required derivatization of samples to extract gabapentin from biological samples is due to 
its zwitterionic characteristic (Figure 1A).  The additional work-up steps are to produce a chromophore 
so it can be analyzed using the analytical techniques mentioned above. The extraction processes (multi-
step liquid-liquid or solid-phase extractions) all increase sample preparation time as well as the cost of 
the method. They also do not produce the most precise results as their limits of detection are larger 
than LC-MS methods mentioned above. For this reason, a high performance liquid chromatography 
electrospray ionization time-of-flight mass spectroscopy (HPLC-ESI-TOF-MS) method was employed to 
quantify GBP quickly, accurately, and at a lower long term cost than previous methods as the sample 
preparation does not require such extensive extraction processes.  
 
1.2 Analysis  
The samples of tissue serum are introduced into high performance liquid chromatography 
(HPLC) analysis by an autosampler. The HPLC serves to separate the biological sample into various 
groups of molecules based on the molecules characteristics such as polarity and size. This occurs due to 
different interactions between the stationary phase and mobile phase of the column.  
The HPLC is coupled to Agilent Jet Stream Electrospray Ionization (AJS ESI) technology, which will 
operate in positive mode for this purpose, and is a very sensitive ion source for this sample type. It 
incorporates high velocity heated gas to generate large amounts of analyte ions while including an 
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internal mass reference spray (IRM). The sample ions are related to the IRM ions from within each 
individual scan. Using the relative mass differences provides very accurate (<2ppm accuracy) and precise 
(down to 100 Daltons mass range) mass measurements.20  
The ESI creates positively charged ions (Figure 2) for analysis by nebulizing the IRM and sample 
solution flow from the HPLC into the ESI spray chamber using nitrogen as the nebulizing gas. The 
droplets in the spray chamber are dried using heated nitrogen which evaporated the droplets until they 
reach the Rayleigh limit in which the positive charge builds up on the droplet such that the droplet goes 
through a Columb explosion. These smaller droplets are dried again and again in the chamber until just a 
positively charged analyte ion is left.  
 
Figure 2: Proposed chemical structures of protonated gabapentin 
 
A dielectric platinum-plated capillary separates the spray chamber from the ion optic region. A 
voltage is applied to the front end of the capillary (Vcap) in order to maximize transmission of the  
positively charged ions formed in the atmospheric spray chamber as they travel through the capillary to 
the lower pressure ion optic region where they are focused and introduced into the mass analyzer.21  
 The pressure drop exiting the capillary creates a supersonic beam that produces a Mach disk 
between the capillary and the first skimmer. The skimmer serves to sample the ions, putting the 
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skimmer after the Mach disk increases sensitivity before the ion proceeds into the octopole.  The 
octopole reduces the ion energy distribution before mass analysis and consists of eight rods with RF 
voltage in addition to a DC offset voltage (adjacent rods have opposite polarity voltages).22 Finally, the 
ion beam goes through two lenses before entering the mass analysis portion of the instrument. The first 
lens serves as an electrostatic lens to focus the ions and the second lens has an RF voltage applied to it 
which pumps away most of the excess neutrals.23  
Once in the flight tube, the ions are pushed into flight by an ion pulser. The ion pulser is made of 
a stack of plates, each (except the last, back plate) with a hole in the center. The ions enter the stack of 
plates between the back plate and the first plate with a hole in the center. A high voltage is applied to 
the back plate which accelerated the ions through the holes in the stack of plates to create a beam of 
ions.24 The beam of ions fly up into the flight tube. 
At the end of the flight tube there is a two stage ion mirror. This ion mirror utilizes plates of 
increasing electrical potential to slow ions as they penetrate deeper into the plates on the top of the 
light tube (Figure 3). This increases the accuracy of mass measurements as spatial and kinetic energy 
distributions (Figure 4) are minimized. 
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Figure 3: Ion mirror equalizes arrival time of two ions of the same mass at the detector25 
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Figure 4: Variation in flight time illustrated 
 
The ions then reach the surface of the ion detector due to a charged surface used to attract the 
ions. The surface of the ion detector is comprised of microscopic tubes that pass from the surface to the 
C 
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C 
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rear of the microchannel plate (MCP). When the ion strikes the surface, an electrical signal amplification 
process takes place. When the MCP is struck, an electron becomes free and hits the walls of a 
microscopic tube which causes more electrons to become free and this continues as an increasing 
number of electrons travel to the rear of the plate through the microscopic tube. These electrons are 
then focused on a scintillator which produces a flash of light when struck by electrons. This light is then 
focused through two small lenses onto a photomultiplier tube (PMT). This electrical signal is then read 
by the data system. An optical signal is created from the MCP signal because the MCP output is 
approximately -6000 V while the PMT output is at ground potential.26  
Fundamentally, a time of flight mass spectrometer (TOF-MS) measures time, not mass. It 
employs fundamental laws to calculate mass from the time of flight.  
It is widely accepted that the speed of an electron is proportional to the voltage applied in 
acceleration (Equation 1).  
𝑒𝑉 =
1
2
𝑚𝑣2 
Equation 1: Speed of an electron.27 
 
The speed is proportional to the length of the path traveled and the time it took to travel that 
length (Equation 2).  
𝑣 =
𝐿
𝑡
 
Equation 2: Speed is proportional to length and time of path traveled.27 
 
One can combine the above equations one and two to give an equation that gives us an 
equation of time based on the mass and charge of an ion (Equation 3). 
e= charge of an electron 
V= voltage applied in acceleration 
m= mass of an electron 
v= speed 
v= speed 
L= length of flight path 
t= time 
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𝑡 = 𝐿√
𝑚
2𝑒𝑉
 
Equation 3: time calculated from length of flight path, mass and charge of an electron, and voltage applied in acceleration.27 
 
One is able to measure the time of flight in the TOF-MS. The length of the flight tube is 
consistent and known and the voltage applied in acceleration is known. One can then measure the 
mass-to-charge ratio of the analyte based on equation four.  
𝑚
𝑧
= (
2𝑉
𝐿2
) 𝑡2 
Equation 4: Mass to charge ratio calculated from time, length of flight path, and voltage applied.27 
 
The flight tube is also under high vacuum (9.6 x 10-8 Torr) so no other particles interfere with the 
flight pattern. The TOF pulse plate pulses ions into flight about every 100 microseconds while the 
detector takes a measurement every one nanosecond, equivalent to one billion spectra per second. 
There are 100,000 data points in each transient. This all equates to spectra with excellent ion statistics.28 
 
2. Methodology 
2.1 Materials 
Gabapentin (G154) was obtained from Sigma- Aldrich (St. Louis, MO). Sterile latex-free syringes, 
1 mL norm-ject tuberkulin, were purchased from Henke Sass Wolf (Tuttlingen, Germany) with sterile 
precision glide needles 22G1½ from Becton Dickinson & Co. (Franklin Lakes, NJ, USA). Microvials used 
for sample analysis were purchased from MicroSolv Technology (Eatontown, NJ, USA). Captiva 
regenerated cellulose syringe filters (pore size 0.2 μm, Product: 5190-5106, Lot: 1308004VS) were 
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purchased from Agilent Technologies (Wilmington, DE, USA). HPLC grade acetonitrile with 0.1 % formic 
acid (Product: HB9823-4, Lot: 143003), HPLC grade water with 0.1 % formic acid (Product: HB523-4,  
Lot: 138713), and ACS grade (99.7%) caffeine (Product: AA39214-14, Lot: G31Z005) were purchased 
from Fisher Scientific (Ann Arbor, MI, USA). HPLC ready deionized 18 MΩ-cm water was obtained,  
in-house, from a Barnstead NANOpure infinity base unit analytical version model D8961, Barnstead/ 
Thermolyne Corp., (Dubuque, IA, USA).   
 
2.2 Instrumentation and conditions 
 An Agilent 1290 Infinity LC Injector HTC (CTC PAL), (Agilent Technologies, Wilmington, DE, USA), 
autosampler introduced the samples into the HPLC-ESI-TOF-MS system. Wash solvent A was acetone in 
water with 0.1 % formic acid and wash solvent B was 1:1:1 acetonitrile-dichloromethane-methanol. The 
wash solvents were used to wash both the inside and the outside of the injection needle between each 
injection to prevent sample cross-contamination. A sample volume of 5 μL was used during the 
injection. The aliquot was used to first flush the sample loop in the six-port injection valve before the  
2 µL sample loop was filled and the sample was injected into the instrumentation. 
The HPLC 1290 Infinity LC system consists of a Hewlett Packard series (Agilent Technologies, 
Wilmington, DE, USA) equipped with a Jet Weaver V35 mixer, a G1316C thermostatted column 
compartment (TCC), and G4212A diode-array detector (DAD). A Zorbax Eclipse Plus C18 Rapid 
Resolution HD (RRHD) column, 2.1 mm x 50 mm, 1.8 μm (Product: 959757-902, Lot: B11048) fitted with 
a filter installed ahead of the column was used in the separation method. The elution was an optimized 
gradient between solutions A (5% acetonitrile in water) and solution B (95% acetonitrile in water). A 
linear gradient from 95:5 to 5:95 A-B for 9.5 minutes followed by isocratic 5:95 A-B conditions for  
2.0 minutes and a gradient back to 95:5 A-B conditions for the last 0.5 min all at 0.100 mL/min flow rate. 
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The column pressure was limited to 600 bar and temperature was maintained at 20 °C. The column 
eluent was analyzed by TOF-MS, using positive ESI.  
 The nitrogen used as the drying gas in the ESI-TOF was obtained in house from a Parker 
Nitroflowlab, Parker Filtrations & Separation B.V. (Etten-Leur, Netherlands). It was at minimum 98 % 
pure and introduced into three big universal traps in parallel before entering the ESI. The nitrogen 
drying gas was pumped into the nebulizer at 25 psig at 9 L/min. It was also used as the sheath gas 
flowing at 8 L/min.  
An ESI-TOF-MS 6230A (Figure 5) (Agilent Technologies, Wilmington, DE, USA), was run in 
positive mode and a fast switch capillary 0.6 mm (Product: G1960-80060) from Agilent was employed. 
The ion source was Agilent jet stream electrospray ionization (AJS ESI) with gas temperature at 325 °C. 
The VCap was set to 2750 V and the nozzle voltage was 500 V. The MS TOF fragmentor was 175 V, the 
skimmer was 65 V, and the octopol 1 RF Vpp was 750 V. The TOF spectra was collected in the range of 
100 m/z to 1000 m/z at an acquisition rate/time of 3 spectra/second and time 333.3 ms/spectrum. The 
transients/spectrum was 3285. Both a TIC and BPC chromatograms were collected. While the samples 
ran, a reference mass solution was also pumped through the TOF-MS with references masses of 
118.086255 m/z and 922.009798 m/z at a detection window of 100 ppm with a minimum height of  
400 counts.  
All instrumentation was ran with Agilent MassHunter workstation software LC/MS data 
acquisition for 6200 series TOF, version B.05.01, Build 5.01.5125.1.  
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Figure 5: TOF-MS diagram 
 
3. Experimental Procedure 
3.1 Preparation of internal standard solution 
 A batch of 10 ppm caffeine solution was prepared in lab and provided to our collaborator,  
Dr. Yan Wang, Department of Neuroscience, to use as an internal standard for sample preparation.  
 
3.2 Biological Preparation of Samples 
 All surgical and post-operative care procedures were performed in accordance with The Ohio 
State University Institutional Animal Care and Use Committee. Age- and weight-matched female 
C57BL/6 mice were obtained from Jackson Laboratories.  
9.6 x 10-8 Torr 
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Mice were a part of one of four dosage and delivery groups or a control group (treatment code 
G˳).  One delivery system was a mini pump which delivers the gabapentin in subcutaneous injections at a 
rate of 0.12 µg/day. Two subgroups were within the mini pump group which included administering the 
drug in a phosphate buffered saline (PBS) for either one week (treatment code 1) or three weeks 
(treatment code 2) post spinal injury. Another delivery system was investigated, hand injections 
subcutaneously with 10 mg/mL gabapentin in PBS solution with the dosage of 200 mg/kg/day (mg of 
drug/ kg of body weight) for 8 days. Two subgroups were within this delivery system as well. Mice either 
received the injections every 2 hours (treatment code 3) or every 32 hours (treatment code 4).  
A sample of tissue (10-100 mg) was obtained and homogenized in 200 μL of internal standard 
solution of caffeine in water (10 ppm caffeine). A simple protein precipitation with acetonitrile (1600 μL) 
was implemented. The sample was then vortexed for 30 seconds then centrifuged at 13,000 xG for  
10 minutes at 4 °C.  The clear supernatant was then transferred to a clean 1.5 mL conical bottom tube 
and dried completely under a gentle stream of nitrogen gas. The dried samples were then stored at  
-80 °C until analysis.  
 
3.3 Preparation of Samples for Analysis 
 The dried samples were brought to room temperature and reconstituted with 200 μL of 
nanopure water (18 MΩ-cm or greater). The samples were filtered through Agilent Captiva regenerated 
cellulose syringe filters (pore size 0.2 μm) into 300 μL autosampler microvials for analysis. 
 
3.4 Creation of calibration curves 
 Standard solutions of gabapentin were created in water in the range of 0 ppb to 95 ppm 
gabapentin each spiked with the internal standard, 10 ppm caffeine. The solutions were analyzed 
19 
 
according to the above instrumentation and conditions. The responses from the known concentrations 
were used to create a calibration curve (Graph 1 and 2) (MassHunter Quantitative CurveFit Assistant) 
and used by the data analysis program to quantify the unknown concentrations of gabapentin in the 
biological samples.  
 
3.5 Quantification method of drug in tissue sample 
 A basic quantification workflow was created in MassHunter Workstation software, Quantitative 
analysis version B.06.00 SP01, Build 6.0.388.1. A batch was created from analytical runs of calibration 
solutions and tissue samples. A method was created from the standards in the batch and information on 
the calibration levels and internal standard levels.  The quantification method was verified within the 
program before being applied to the batch. The calibration curve fit options were explored to choose 
the best fit line. The integrations of the peaks were manually confirmed to verify the method created. 
Any messages and outliers that the program flagged were also addressed.  
 
4. Results 
4.1 MassHunter quantification method 
 The method was developed with the help of the MassHunter Program. A new method used 
acquired data from a concentrated calibration solution (95 ppm) to create the method. The software 
identified quantifiers from the TIC scan as suggested ions to quantify. Both gabapentin and caffeine 
were identified from the TIC scan and were marked as quantifiers. The caffeine mass peak was identified 
as 195.0892 m/z (±0.0049 m/z: standard deviation of the mass measurement, calculated in appendix) 
and the gabapentin mass peak was identified at 172.1348 m/z (±0.0094 m/z: standard deviation of the 
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mass measurement, calculated in appendix). The caffeine was marked as the internal standard (ISTD in 
the program) and concentration was entered as 10,000 ppb as the program quantifies in unit terms of 
ppb (µg/L).  
 New calibration levels were added to include the calibration range from 0 ppb – 95 ppm, 
concentrations of GBP, with 10 ppm ISTD in each sample. The method was validated within the program 
and applied to analyze the batch of spinal samples and calibration solutions. 
 
4.2 Calibration curve  
A range of calibration solutions (0 ppb – 95 ppm) were used to create the calibration curve 
which was later used to quantify the spinal samples based on their response (counts). The calibration 
curve was found to be linear in the range of 0 ppb to 5 ppm (y = 0.849085x + 0.004602 (R2=0.97902938)) 
(Graph 1) but behave in a power fashion in the extended range 0 ppb to 95 ppm (y = 0.646127x0.766702  
(R2 = 0.99490159)) (Graph 2).  
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Graph 1: Linear Calibration curve in concentration range 0 ppb to 5000 ppb with confidence bands. 
 
 
 
Graph 2: Power Calibration curve in concentration range 0 ppb to 95 ppm with confidence bands. 
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4.3 Verification of calibration curve 
 Calibration solutions were run as samples to verify the calibration curve and the MassHunter 
quantification method. A few calibration solutions across the concentrations were chosen for analysis. 
The verifications were run on different days along with the animal sample runs and the gabapentin 
quantifications (Table 1) were calculated with the animal samples using the same quantification method 
as the animal samples.  
 
Table 1: Calibration solutions run as samples for calibration curve verification 
 
4.4 Drug quantification in spinal cord   
Using the quantification method paired with the calibration curve, the spinal cord samples were 
examined for caffeine and gabapentin concentrations. The program identified and integrated the mass 
peaks and compared the counts of gabapentin peaks to the counts of the calibrated ISTD and the 
calibration curve. From this, the program was able to quantify the amount of gabapentin in each sample 
(Table 2).  
 
 
Name 
Gabapentin 
Response 
(counts) 
Calculated 
Concentration (ppb) 
Accuracy 
Within confidence 
limits? 
Calibration test 1000 ppb 
gabapentin 
4415361.907 1550 155% Yes 
Calibration test 1500 ppb 
gabapentin 
4343230.052 1390 92.8% Yes 
Calibration test 2500 ppb 
gabapentin 
7528907.739 2800 112% Yes 
Calibration test 7000 ppb 
gabapentin 
9560688.645 7510 107% Yes 
Calibration test 35000 ppb 
gabapentin 
28341692.07 34960 99.9% Yes 
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Table 2: Gabapentin concentrations in each animal sample.  
Animal 10 sample was damaged in preparation and not included in the drug quantification process.  
 
These values were obtained in a blinded experiment method in which the analytical chemist did 
not know which animals got what dosage of drug, which treatment method, or if they were treated at 
all. This form of experimentation is meant to withhold information not necessary to the step of the 
process in order to remove the possibility (intentional or unintentional) of the formation of a bias. The 
analytical chemist was informed of the test groups after the quantification was finalized for each animal 
sample, only then were the delivery and dosage methods investigated (Table 3) (Graph 3).  
 
 
 
 
 
Name 
Gabapentin 
Response (counts) 
Calculated 
Concentration (ppb) 
Gaba Ctrl SC 0 0 ±1030 
Gaba AC Ctrl 0 0 ± 1030 
Animal 1 534740.3723 850 ± 1030 
Animal 2 644635.8086 2680 ±1030 
Animal 3 810804.6474 2160 ±1030 
Animal 4 1907171.441 33740 ±1040 
Animal 5 872422.8221 2640 ±1030 
Animal 6 633313.498 2530 ±1030 
Animal 7 474312.2695 2540 ±1030 
Animal 8 424773.1187 2470 ±1030 
Animal 9 3659180.375 37190 ±1040 
Animal 11 806740.9229 5930 ±1030 
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Name 
Calculated 
Concentration (ppb) 
Treatment 
Code 
Treatment Method 
Gaba Ctrl SC 0 G˳ None 
 
Gaba AC Ctrl 0 G˳ None 
Animal 1 850 2 mini pump 3 weeks 0.12ug/day 
Animal 2 2680 2 mini pump 3 weeks 0.12ug/day 
Animal 3 2160 2 mini pump 3 weeks 0.12ug/day 
Animal 4 33740 3 200mg/kg/day subcutaneous injection for 8 days 
at 2hr after last injection  
Animal 5 2640 1 mini pump 1 weeks 0.12ug/day 
Animal 6 2530 1 mini pump 1 weeks 0.12ug/day 
Animal 7 2540 1 mini pump 1 weeks 0.12ug/day 
Animal 8 2470 4 200mg/kg/day subcutaneous injection for 8 days 
at 32hr after last injection  
Animal 9 37190 3 200mg/kg/day subcutaneous injection for 8 days 
at 2hr after last injection  
Animal 11 5930 4 200mg/kg/day subcutaneous injection for 8 days 
at 32hr after last injection  
 
Table 3: Gabapentin concentration paired with treatment method for each animal 
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Graph 3: Average gabapentin concentrations, with error bars, in animal samples per treatment method 
 
5. Discussion 
 The internal standard caffeine concentration was 10 ppm in each animal sample and calibration 
solution. After testing a range of caffeine concentrations (100 ppm, 50 ppm, 10 ppm, 1 ppm) 10 ppm 
was concluded to be the best option for analysis purposes. A concentration of 10 ppm caffeine was 
suitable due to a clear response peak without over saturating the detector or creating any ion 
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suppression of other analytes (Calibration investigation results in Appendix). The concentration 1 ppm 
had a narrow Gaussian shaped peak but only was detected at 250,000 counts at the peak. While this can 
be considered a good response, the 10 ppm concentration yielded approximately 3,700,000 counts at 
the signal peak which is more ideal. Concentrations of 50 ppm and 100 ppm also yielded response 
counts over 4 million, and while these did not over saturate the detector, too large of a count response 
can cause ion suppression of other analytes. The internal standard concentration of 10 ppm was also the 
most symmetric compared to the 50 ppm and 100 ppm concentrations. The 50 ppm and 100 ppm had 
tailing peaks and while some degree of tailing is unavoidable, performance of the data system starts to 
be compromised when the tailing becomes too large.  It is for these reasons that the concentration of  
10 ppm caffeine was used as the internal standard in this investigation rather than 1 ppm, 50 ppm, or 
100 ppm. These values were evaluated in Agilent MassHunter workstation Qualitative analysis software, 
version B.06.00, Build 6.0.633.10, service pack 1 with bio confirm software.  
 The calibration curve is linear at lower concentrations of GBP but takes on a power series trend 
as the concentrations of GBP extend beyond 5 ppm to 95 ppm. Different proposals as to why the higher 
concentrations deviate from linearity have been proposed. The first is that there is a limited amount of 
excess charge available on ESI droplets to the point where analyte concentration can exceed the charges 
available.29 A second conclusion to this trend is that there is limited space on a droplet surface and once 
the concentration approaches a certain limit, the surface becomes so saturated with analyte that ion 
ejection becomes inhibited because ions are trapped in the droplet interior.30 A third possible cause is 
suppression and competition at high concentrations. For example, a surface-active analyte would be 
expected to out-compete polar analytes for the limited excess charge and/or space on the droplet 
surface as previously discussed.31 Regardless of the reason, which is still not well established, the power 
series deviation from linearity is typical and expected for higher concentrations of analyte analysis.  
 
27 
 
As seen in the results (Table 1-2) there are a fractional number of counts of analyte ions as well 
as a large number of significant figures. Both the fractional counts and the large number of significant 
figures can be attributed to the detection method used in an HPLC-ESI-TOF-MS.  The detector plate is a 
microchannel plate (MCP) comprised of many microscopic tubes or channels. The MCP is negatively 
charged to attract the positively charged analyte ions. When an ion hits the MCP, one or more electrons 
are released inside a channel which acts as an electron multiplier. Electrons cascade down the channel 
and exit at about ten electrons per ion that hit the surface of the MCP. When the electrons exit the 
channel, they are accelerated into a scintillator which emits photons when struck by electrons. The 
photons that are released from the scintillator are focused through optical lenses onto a photomultiplier 
tube (PMT). The PMT then produced an electrical signal proportional to the number of photons. The 
detection signal is converted from an electrical signal to an optical signal and then back to an electrical 
signal as to electrically isolate the flight tube and the detector which are roughly -6500 V, from the PMT, 
which outputs a signal at ground potential. 27  
During method development, it was noted that the column in the HPLC started to get 
contaminated by the high amounts of analytes that were run through the column. This issue was 
addressed by including an additional two minutes of run time to the end of each sample run that served 
as a wash between sample runs. This built in wash was two minutes of 5:95 ratio of 5% acetonitrile in 
water with 0.1 % formic acid and 95% acetonitrile in water with 0.1 % formic acid. This added wash time 
not only allowed the column to be flushed between samples to keep the column free from analyte build 
up but this also prevented cross contamination between sample runs as well.  
The results obtained in this research show that the method developed was able to detect and 
quantify gabapentin concentrations in a large range in animal tissue. Given these results, The Ohio State 
University Neuroscience research group will use the dosage of 200 mg/kg/ day for 8 days giving 
subcutaneous injections every 2 hours after the last injection of gabapentin method in a future, full scale 
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gabapentin experiment to characterize any healing properties GBP could have in post spinal cord injury 
cases and prevent future onset of AD.  
 Further, more detailed experiments performed by the Neuroscience department will require a 
more vigorous calibration curve and quantification method. Future work in the analytical development 
will include a calibration curve for gabapentin created in blank tissue samples rather than just solutions 
as done in this step of the research.  This calibration in tissue will provide a comprehensive picture of 
any matrix effects that may be present such as if the gabapentin takes on a sodium or potassium ion as 
opposed to a hydrogen ion when being analyzed. If this occurs, other mass peaks will need to be 
considered when quantifying the gabapentin in the tissue samples.  This calibration in tissue 
concentrations will also be tested in triplicates across various days/ hours to obtain a more accurate 
calibration curve to use in a large scale experiment.  
At this stage, the research project was to explore dosage and delivery methods as compared to 
one another, such that this vigorous of a calibration curve was not necessary. Using the calibrations in 
solution, the quantification method was able to show a seven to ten fold drug presence (on average) in 
the 200 mg/kg/ day for 8 days at 2 hours after last injection gabapentin as compared to the other three 
dosage and delivery methods examined. This shows a clear difference in drug presence in the spinal 
cord given a different dosage and delivery method.  
 Further work will also include quantifying gabapentin in other tissue samples from the mice. In 
addition to spinal cord samples, brain, kidney, and spleen samples will be tested for gabapentin 
concentrations as well. This will give neuroscientists a better look at how the drug is affecting other 
body parts in the subject’s system. Side effects such as nausea, diarrhea, constipation, and flu like 
symptoms have been reported with the use of gabapentin for seizure control and neuropathy.32  There 
have even been reports of encephalopathy associated with gabapentin administration.33 These side 
29 
 
effects suggest that gabapentin is interacting with other systems outside the spinal cord and brain and it 
is an important part of the overall picture of how the drug is processed inside the body to know what 
other systems may be up taking the drug. It is also important to know if harmful concentrations are 
being achieved in different tissues within the body as well as seeing if interactions with other systems 
may help or harm the overall healing process.   
 It will also be during this large scale experiment that neuroscientists will be documenting the 
progress of the healing process and if gabapentin does in fact help, hinder, or is neutral in the 
prevention of AD. Knowing the quantity of gabapentin in the possible successful versus unsuccessful 
cases will help neuroscientists alter and perfect the dosage and delivery recommendations for 
gabapentin use in preventing future cases of AD in spinal cord injury patients.  
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Appendix 
Gabapentin positive ion calculated mass (C9H17NO2) + H+ 
 Mass of atom (amu) Number of atoms Sum (amu) 
Carbon 12.00000 9 108.00000 
Hydrogen 1.00783 17 17.13311 
Nitrogen 14.00307 1 14.00307 
Oxygen 15.99492 2 31.98984 
  Total 171.12602 
Plus H 1.00783 1 +1.00783 
  Total 172.13385 
Minus e- 0.00055 1 -0.00055 
  Total 172.13330 
 
Gabapentin calculated mass assignment error  
(172.1348 − 172.1333) ∗ 1000000
172.1333
= 8.714177 𝑝𝑝𝑚 𝑒𝑟𝑟𝑜𝑟 
Gabapentin standard deviation of the mass measurement 
𝑠 =
106
(2.4 ∗ 𝑅 ∗ √𝑛 )
 
0.004883913 =
106
(2.4 ∗ 10000 ∗ √72784960.37 )
 
  
s= standard deviation of the mass 
measurement 
R= resolving power (10,000 for LC/MS TOF)  
n = number of ions detected in mass peak 
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Caffeine positive ion calculated mass (C8H10N4O2) + H+ 
 Mass of atom (amu) Number of atoms Sum (amu) 
Carbon 12.00000 8 96.00000 
Hydrogen 1.00783 10 10.07830 
Nitrogen 14.00307 4 56.01228 
Oxygen 15.99492 2 31.98984 
  Total 194.08042 
Plus H 1.00783 1 +1.00783 
  Total 195.08825 
Minus e- 0.00055 1 -0.00055 
  Total 195.08770 
 
Caffeine calculated mass assignment error  
(195.0892 − 195.0877) ∗ 1000000
195.0877
= 7.688850 𝑝𝑝𝑚 𝑒𝑟𝑟𝑜𝑟 
Caffeine standard deviation of the mass measurement 
𝑠 =
106
(2.4 ∗ 𝑅 ∗ √𝑛 )
 
0.0093979 =
106
(2.4 ∗ 10000 ∗ √19656894.83 )
 
 
 
 
s= standard deviation of the mass 
measurement 
R= resolving power (10,000 for LC/MS TOF)  
n = number of ions detected in mass peak 
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TOF Tune Report  
Tune Type:  TOF  Tune   TOFAutotune  
         
MS Model  G6230A  
Tune Date & Time    03/18/2015 
10:25:12  
Instrument ID   Instrument State Ext Dynamic Range (2 GHz) 
Serial#  SG11050201 SG11050201 SampleRate 2  
Firmware Rev. 4.584 4.5840001   HiRes 0  
Data Path  D:\MassHunter\Tune\TOF\Autotune.tun DualGain 3  
         
Source Type   AJS ESI   Polarity   Positive     
         
TOF Results               
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Calibration Data Table   
m/z Actual Time Abund Res FWHM Delta (m/z) Delta (PPM) 
118.086255 118.086255 20.00125 63449 5734 0.0217 0 0 
322.048121 322.048136 32.36394 63375 8486 0.0392 0.000015 0.05 
622.02896 622.028834 44.57981 35175 10555 0.0603 -0.000126 -0.2 
922.009798 922.010136 54.05267 38501 11724 0.0801 0.000338 0.37 
1221.990637 1221.990362 62.07291 32216 12245 0.1015 -0.000275 -0.22 
1521.971475 1521.971366 69.15545 28368 12740 0.1213 -0.000109 -0.07 
1821.952313 1821.952344 75.56806 19285 13100 0.141 0.000031 0.02 
2121.933152 2121.933633 81.47114 31039 13194 0.1629 0.000481 0.23 
2421.91399 2421.913484 86.96973 24976 13440 0.1823 -0.000506 -0.21 
2721.894829 2721.894981 92.13709 24361 13473 0.2043 0.000152 0.06 
        
Setpoints               
Parameter   Setting Actual  Parameter Setting 
Source     TOF   
Gas Temp  325 325  Pusher  1250 
Drying Gas  5 5  Puller  -800 
Nebulizer Pressure 20 20  Puller Offset 29 
Capillary  4000 -4000  Acc Focus  -1880 
     Front Mirror -6500 
     Mid Mirror  -1391.5 
     Back Mirror 1650 
Sheath Gas Temperature 325  325 Minimum Mass 100 
Sheath Gas Flow  7.5  7.5 Maximum Mass 3200 
Nozzle Voltage  2000  2000 Acquisition Rate 1 
Optics 1     Acquisition Time 1000 
Fragmentor  175   Length of Transients 199632 
Skimmer  62   #Transients / Spectrum 9894 
Oct 1 RF Vpp  750   Low Gain PreAmpOffset 50793 
Oct DC 1  35.8   Gain Abund Ratio 12.0 
     Gain T0 Offset -0.010 
Optics 2        
     Detector  
     MCP  660 
Ion Focus  -160   PMT  761 
Slicer  -9.5   PreAmpOffset 39277 
Horizontal Q  22.8 10     
Vertical Q  23.6      
Top Slit  9   Other Actuals:  
Bottom Slit  7.3   Parameter Actual 
        
     Rough Vac 1.77 
     TOF Vac  9.01E-08 
        
     Capillary Current 7.009 
     Chamber Current 3.76 
     Turbo 1 Speed 100 
     Turbo 1 Power 175 
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Calibration Coefficients (in μs) Flags:   TraditionalWeighting: 
a 0.5726004 a2 1.068E-06 c2 2.7E-09 e2 1.357E-15 
t0 1.023324 b2 -9.41E-08 d2 -2.8E-11 f2 -4.13E-20 
Term Flags: 0x0578 Trad: 1 Poly: 6   
 
 
Calibration Investigation Results 
 
